Company: AVEO Pharmaceuticals
Based: Cambridge, MA
Investors: Bessemer Venture Partners, Biogen Idec New Ventures, Flagship Ventures, GE Equity, Greylock Partners, Highland Capital Partners, Individuals, MPM Capital, Merck & Co., Merlin Nexus, Mitsubishi UFJ Capital Co., Oxford Bioscience Partners, Prospect Venture Partners, Schering-Plough, Undisclosed Corporate Investor, Undisclosed Investor, Venrock Associates
Scoop: AVEO is developing a number of cancer therapies. The company's first product is AV-299, a monoclonal antibody targeting Hepatocyte Growth Factor (HGF). An IND is expected shortly. Recently, OSI Pharmaceuticals and AVEO inked a deal to discover and develop small molecules. The companies hope to develop therapies that target the underlying mechanisms of epithelial-mesenchymal transition in cancer.